Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene and LncRNA in Prostate Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2019 Aug 14

PMID 31405024

Citations 26

Authors

Zikai Chen

Xuhong Song

Qidong Li

Lingzhu Xie

Tangfei Guo

Ting Su

Chang Tang

Xiaolan Chang

Bin Liang

Dongyang Huang

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a common carcinoma in males, the development of which involves the androgen receptor (AR) as a key regulator. AR transactivation induces the high expression of androgen-regulated genes, including transmembrane protease serine 2 () and long noncoding RNA prostate cancer-associated transcript 38 (). and are both located on chromosome 21, separated by a series of enhancers. is a prostate-specific long noncoding RNA that is highly expressed in cancer tissue as compared to normal tissue. Here, we show chromatin looping by enhancers E1 and E2 with the promoters for and , indicating the co-regulation of and by the same enhancers. The knockout of enhancer E1 or E2 simultaneously impaired the transcription of and and inhibited cell growth and migration. Moreover, the loop formation and enhancer activity were mediated by AR/FOXA1 binding and the activity of acetyltransferase p300. Our findings demonstrate the utilization of shared enhancers in the joint regulation of two oncogenes in prostate cancer cells.

Citing Articles

and genetic polymorphisms as potential predictors of COVID-19 severity and outcome in females.

Matic S, Milovanovic D, Mijailovic Z, Djurdjevic P, Stefanovic S, Todorovic D Front Med (Lausanne). 2025; 11:1493815.

PMID: 39744525 PMC: 11688283. DOI: 10.3389/fmed.2024.1493815.

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.

Turpin A, Delliaux C, Parent P, Chevalier H, Escudero-Iriarte C, Bonardi F Br J Cancer. 2023; 129(12):1903-1914.

PMID: 37875732 PMC: 10703930. DOI: 10.1038/s41416-023-02449-x.

Therapeutic Potential of Bioactive Compounds from Edible Mushrooms to Attenuate SARS-CoV-2 Infection and Some Complications of Coronavirus Disease (COVID-19).

Baruah P, Patra A, Barge S, Khan M, Mukherjee A J Fungi (Basel). 2023; 9(9).

PMID: 37755005 PMC: 10532592. DOI: 10.3390/jof9090897.

Long-range gene regulation in hormone-dependent cancer.

Tettey T, Rinaldi L, Hager G Nat Rev Cancer. 2023; 23(10):657-672.

PMID: 37537310 DOI: 10.1038/s41568-023-00603-4.

Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review.

Gioukaki C, Georgiou A, Gkaralea L, Kroupis C, Lazaris A, Alamanis C Int J Mol Sci. 2023; 24(14).

PMID: 37511059 PMC: 10379122. DOI: 10.3390/ijms241411299.

References

Li Q, Su Z, Xu X, Liu G, Song X, Wang R . AS1DHRS4, a head-to-head natural antisense transcript, silences the DHRS4 gene cluster in cis and trans. Proc Natl Acad Sci U S A. 2012; 109(35):14110-5. PMC: 3435198. DOI: 10.1073/pnas.1116597109. View

Xie L, Song X, Lin H, Chen Z, Li Q, Guo T . Aberrant activation of CYR61 enhancers in colorectal cancer development. J Exp Clin Cancer Res. 2019; 38(1):213. PMC: 6532222. DOI: 10.1186/s13046-019-1217-9. View

Foley C, Mitsiades N . Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer. 2016; 7(2):84-103. PMC: 5380740. DOI: 10.1007/s12672-015-0239-9. View

Jin F, Li Y, Dixon J, Selvaraj S, Ye Z, Lee A . A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature. 2013; 503(7475):290-4. PMC: 3838900. DOI: 10.1038/nature12644. View

Tang B, Cheng X, Xi Y, Chen Z, Zhou Y, Jin V . Advances in Genomic Profiling and Analysis of 3D Chromatin Structure and Interaction. Genes (Basel). 2017; 8(9). PMC: 5615356. DOI: 10.3390/genes8090223. View

Hodl M, Basler K . Transcription in the absence of histone H3.2 and H3K4 methylation. Curr Biol. 2012; 22(23):2253-7. DOI: 10.1016/j.cub.2012.10.008. View

Lam M, Cho H, Lesch H, Gosselin D, Heinz S, Tanaka-Oishi Y . Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature. 2013; 498(7455):511-5. PMC: 3839578. DOI: 10.1038/nature12209. View

Taberlay P, Achinger-Kawecka J, Lun A, Buske F, Sabir K, Gould C . Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations. Genome Res. 2016; 26(6):719-31. PMC: 4889976. DOI: 10.1101/gr.201517.115. View

Clinckemalie L, Spans L, Dubois V, Laurent M, Helsen C, Joniau S . Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013; 27(12):2028-40. PMC: 5426606. DOI: 10.1210/me.2013-1098. View

10.

Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G . Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc. 2007; 2(7):1722-33. DOI: 10.1038/nprot.2007.243. View

11.

Han Q, Xu L, Lin W, Yao X, Jiang M, Zhou R . Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2. Oncogene. 2018; 38(16):3019-3032. DOI: 10.1038/s41388-018-0614-4. View

12.

Ong C, Corces V . Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet. 2011; 12(4):283-93. PMC: 3175006. DOI: 10.1038/nrg2957. View

13.

Haeussler M, Schonig K, Eckert H, Eschstruth A, Mianne J, Renaud J . Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016; 17(1):148. PMC: 4934014. DOI: 10.1186/s13059-016-1012-2. View

14.

Kirby M, Hirst C, Crawford E . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x. View

15.

Zhang Y, Pitchiaya S, Cieslik M, Niknafs Y, Tien J, Hosono Y . Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018; 50(6):814-824. PMC: 5980762. DOI: 10.1038/s41588-018-0120-1. View

16.

Weintraub A, Li C, Zamudio A, Sigova A, Hannett N, Day D . YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell. 2017; 171(7):1573-1588.e28. PMC: 5785279. DOI: 10.1016/j.cell.2017.11.008. View

17.

Li W, Notani D, Rosenfeld M . Enhancers as non-coding RNA transcription units: recent insights and future perspectives. Nat Rev Genet. 2016; 17(4):207-23. DOI: 10.1038/nrg.2016.4. View

18.

James N, Spears M, Clarke N, Dearnaley D, de Bono J, Gale J . Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2014; 67(6):1028-1038. DOI: 10.1016/j.eururo.2014.09.032. View

19.

Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti M, Zanotti L . Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. Eur J Cancer. 2016; 61:111-21. DOI: 10.1016/j.ejca.2016.04.002. View

20.

Heinz S, Romanoski C, Benner C, Glass C . The selection and function of cell type-specific enhancers. Nat Rev Mol Cell Biol. 2015; 16(3):144-54. PMC: 4517609. DOI: 10.1038/nrm3949. View